Abatacept in the treatment of rheumatoid arthritis

Therapeutics and Clinical Risk Management

Volumn 2, Issue 4, 2006, Pages 365-375

  Vital, Edward M ^a   Emery, Paul ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Abatacept; Disease modifying antirheumatic drugs; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1 ANTIBODY; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMORBIDITY; DISEASE ACTIVITY; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION; INJECTION SITE REACTION; LOW DRUG DOSE; LYMPHOCYTE ACTIVATION; NEOPLASM; NONHUMAN; OPTIMAL DRUG DOSE; PATHOGENESIS; PSORIASIS; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; TLYMPHOCYTE;

EID: 33845414970     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: 10.2147/tcrm.2006.2.4.365     Document Type: Review

References (35)

1. Buch M, Boyle D, Saleem B, et al. 2005. The selective co-stimulation modulator abatacept decreases synovial inflammation and expression of pro-inflammatory cytokines in patients with rheumatoid arthritis. Arthritis Rheum, 52(Suppl):S446.
2. Davis PM, Nadler SG, Suchard SJ, et al. 2005. Abatacept differentially modulates human B-cell and dendritic cell stimulated T-cell effector function. Ann Rheum Dis, 64(Suppl III): 128.
3. Davidson A, Diamond B, Wofsy D, et al. 2005. Block and tackle: CTLA4Ig takes on lupus. Lupus, 14:197-203.
4. Dougados M, Sherrer Y, Carrabba M, et al. 2005. Abatacept provides significant and clinically meaningful efficacy in rheumatoid arthritis patients with inadequate responses to anti-TNF therapy: disease activity score 28 assessments in the ATTAIN trial. Ann Rheum Dis, 64(Suppl III):458.
5. Ehrenstein MR, Evans JG, Singh A, et al. 2004. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med, 200:277-85
6. Emery P, Combe B, Nuamah I, et al. 2004. Patients with rheumatoid arthritis treated with abatacept (CTLA4Ig; BMS-188667) report rapid improvements in pain, disease activity and physical function. Ann Rheum Dis, 63(Suppl I):525
7. Emery P, Russell A, Tate G, et al. 2005. Abatacept induces sustained improvements in health-related quality of life, sleep quality and fatigue over 3 years in rheumatoid arthritis patients with inadequate methotrexate responses. Ann Rheum Dis, 64(Suppl III):403.
8. Emery P, Westhovens R, Leon G, et al. 2005. Benficial effects of the selective co-stimulation modulator abatacept on biomarkers of rheumatoid arthritis immunopathology in patients with an inadequate response to methotrexate or TNF-inhibitor treatment. Ann Rheum Dis, 64(Suppl III):432.
9. Genant H, Peterfy C, Paira S. 2005. Abatacept significantly inhibits structural damage progression as assessed by the genant-modified sharp scoring system in rheumatoid arthritis patients with inadequate response to methotrexate. Ann Rheum Dis, 64(Suppl III):56.
10. Genovese M, Schiff M, Luggen M et al. 2005. Efficacy of Abatacept following wash-out of anti-TNF therapy in rheumatoid arthritis patients in the ATTAIN (Abatacept Trial in Treatment of Anti-TNF Inadequate Responders) Trial: current versus prior discontinuation. Arthritis Rheum, 52:S560-1
11. Genovese MC, Becker JC, Schiff M, et al. 2005. Abatacept for Rheumatoid Arthritis refractory to tumour necrosis factor a inhibition. N Engl J Med, 353:1114-23.
12. Gough SCL, Walker LSK, Sansom DM. 2005. CTLA4 gene polymorphism and autoimmunity, Immunol Rev, 204:102-15.
13. Jenkins MK, Taylor PS, Norton SD, et al. 1991. CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J Immunol, 147:2461-6.
14. Kremer JM, Westhovens R, Leon M, et al. 2003. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med, 349:1907-15.
15. Kremer JM, Westhovens R, Abud-Mendoza C, et al. 2005. Abatacept improves American College of Rheumatology responses and disease activity score 28 remission rates in both recent-onset and more established rheumatoid arthritis: results from the AIM trial. Arthritis Rheum, 52:S562-3.
16. Kremer J, Shergy W, Tindall E, et al. 2004. Sustained clinical efficacy demonstrated by the selective eo-stimulation modulator abatacept (CTLA4Ig) in combination with methotrexate at 2 years in rheumatoid arthritis patients with an inadequate response to methotrexate. Arthritis Rheum, 50:S182,
17. Kremer JM, Dougados M, Emery P, et al. 2005. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept - twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum, 52:2263-71.
18. Linsley PS, Brady W, Urnes M. 1991. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med, 174:561-9
19. Mima T, Saeki Y, Ohshima S, et al. 1995. Transfer of rheumatoid arthritis into severe combined immunodeficient mice. The pathogenetic implications of T cell populations oligoclonally expanding in the rheumatoid joints. J Clin Invest, 96:1746-58.
20. Moreland LW, Alten R, Van den Bosch F, et al. 2002. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum, 46:1470-9.
21. Moreland L. 2005. Unmet needs in rheumatoid arthritis. Arthritis Res Ther, 7(Suppl 3):S2-8.
22. Nadler S, Townsend R, Mikesell G, et al. 2004. Abatacept (CTLA4-IG; BMS-188667) significantly inhibits T-cell proliferation in vitro at clinically relevant concentrations. Ann Rheum Dis, 63(suppl):142.
23. Ndejembi MP, Patke DS, Bingaman AW, et al. 2005. CTLA4-Ig treatment promotes loss of antigen-activated effector memory CD4 T-cells. Arthritis Rheum, 52(Suppl):S492-3.
24. Ponchel F, Morgan AW, Bingham SJ, et al. 2002. Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis. Blood, 100:4550-6
25. Russell A, Emery P, Kafka SP, et al. 2005. Abatacept improves clinical responses regardless of baseline physical function: results from the AIM trial. Arthritis Rheum, 52:S543
26. Sakaguchi N, Takahashi T, Hata H, et al. 2003. Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature, 426:454-60.
27. Salazar-Fontana LI, Sanz E, Me'rida et al. 2001. Cell surface CD28 levels define four CD41 T cell subsets: abnormal expression in rheumatoid arthritis. Clin Imm, 99:253-65
28. Schiff M, Dougados M, Luggen M, et al. 2005. Abatacept leads to significant improvements in all American college of rheumatology core components in patients with an inadequate response to anti-TNF therapy in the ATTAIN trial. Ann Rheum Dis, 64(Suppl III):435.
29. Symington FW, Brady W, Linsley PS. 1993. Expression and function of B7 on human epidermal langerhans cells. J Immunol, 150:1286-95.
30. Talamo J, Frater A, Gallivan S, et al. 1997. Use of the short form 36 (SF36) for health status measurement in rheumatoid arthritis. Br J Rheumatol, 36:463-9.
31. + regulatory T cell function. Eur J Imm, 34:2996-3005.
32. Townsend RM, Kliwinski C, Kukral D, et al. 2005. Prophylactic administration of abatacept prevents disease induction and bone destruction in a rat model of collagen-induced arthritis. Ann Rheum Dis, 64(Suppl III):439.
33. Vincenti F, Larsen C, Durrbach A, et al. 2005. Costimulation blockade with belatacept in renal transplantation. N Engl J Med, 353:770-81.
34. Weinblatt M, Combe B, White A, et al. 2005. Safety of abatacept in patients with active rheumatoid arthritis receiving background non-biologi and biologic DMARDs: 1 year results of the ASSURE trial. Ann Rheum Dis, 64(Suppl III):60.
35. Weisman M, Durez P, Hallegua D, et al. 2004. Abatacept (CTLA4; BMS-188667) inhibits T-cell activation and the subsequent activation of inflammatory cell types, as demonstrated by sustained reductions in multiple inflammatory biomarkers. Ann Rheum Dis, 63(Suppl I):138